Pharvaris (PHVS)
(Delayed Data from NSDQ)
$18.77 USD
+0.53 (2.91%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $18.56 -0.21 (-1.12%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHVS 18.77 +0.53(2.91%)
Will PHVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHVS
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
PHVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know
Other News for PHVS
Pharvaris Shareholders Approve Key Resolutions
Morgan Stanley Remains a Buy on Pharvaris (PHVS)
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Schedules 2024 Shareholder Meeting
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Pharvaris (PHVS) and Cue Biopharma (CUE)